CLINICAL TRIALS PROFILE FOR PEGINTERFERON ALFA-2A

All Clinical Trials for peginterferon alfa-2a

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001854 ↗	Long-Term Therapy With Ribavirin for Chronic Hepatitis C	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 4	1999-02-12	Chronic hepatitis C is a disease of the liver caused by the hepatitis C virus. The disease can be serious and even fatal. Approximately 25% of patients with chronic hepatitis C will develop cirrhosis and some of these patients will develop cancer of the liver or liver failure. Presently the disease is treated with a combination of alpha interferon or peginterferon (antiviral and immune stimulating drugs) and ribavirin (an antiviral drug). Alpha interferon is given by injection three times a week whereas peginterferon is given by injection only once a week. Ribavirin is given as a tablet by mouth twice a day. The combination therapy is given for 6 to months. About half of the patients given these medications will receive a lasting benefit and many patients do not respond well to the combination therapy. This study will select up to 50 patients will chronic hepatitis C who have not responded to combination therapy or who could not stand the side effects associated with interferon or peginterferon therapy. These subjects will be evaluated and undergo liver biopsy to determine their present liver condition. If selected as subjects they will be started on single drug therapy with ribavirin. The drug will be given orally twice a day at a dose based on the patient's body weight. The patients will be followed on an out-patient basis. They will we asked to return for regular check-ups and blood tests every 2 to 8 weeks for the duration of the study. After 6 months, the medication will be stopped or adjusted based on the results of the subject's blood tests (liver enzymes). A response is considered if a decrease of 50% or more of the initial liver enzyme (alanine aminotransferase, ALT) is noted. A complete response will be considered if liver enzymes return to normal levels. Therapy will be discontinued after 6 months if patients do not respond. However, patients that respond to the single drug therapy will continue to receive the medication at a decreased dose. The patients will remain on an appropriate dose for up to 8 years with repeat liver biopsies at 2, 4 and 8 years to assess progress. This study will determine if long-term therapy with ribavirin is safe and effective.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	Hoffmann-La Roche	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
NCT00006164 ↗	Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	2000-06-01	The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months. Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits. The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial. The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.

Clinical Trial Conditions for peginterferon alfa-2a

Condition Name

Condition Name for peginterferon alfa-2a
Intervention	Trials
Hepatitis C, Chronic	126
Hepatitis C	104
Chronic Hepatitis C	85
Chronic Hepatitis B	38

Condition MeSH

Condition MeSH for peginterferon alfa-2a
Intervention	Trials
Hepatitis	414
Hepatitis A	379
Hepatitis C	345
Hepatitis, Chronic	270

Clinical Trial Locations for peginterferon alfa-2a

Trials by Country

Trials by Country for peginterferon alfa-2a
Location	Trials
Canada	209
Italy	131
China	125
Australia	118
Germany	118

Trials by US State

Trials by US State for peginterferon alfa-2a
Location	Trials
California	110
Texas	100
New York	91
Florida	83
Maryland	83

Clinical Trial Progress for peginterferon alfa-2a

Clinical Trial Phase

Clinical Trial Phase for peginterferon alfa-2a
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE2	1

Clinical Trial Status

Clinical Trial Status for peginterferon alfa-2a
Clinical Trial Phase	Trials
Completed	340
Terminated	48
Unknown status	47

Clinical Trial Sponsors for peginterferon alfa-2a

Sponsor Name

Sponsor Name for peginterferon alfa-2a
Sponsor	Trials
Hoffmann-La Roche	103
Merck Sharp & Dohme Corp.	52
Vertex Pharmaceuticals Incorporated	23

Sponsor Type

Sponsor Type for peginterferon alfa-2a
Sponsor	Trials
Other	380
Industry	367
NIH	37

Peginterferon alfa-2a: Clinical-trials update, market analysis, and projection

Last updated: April 24, 2026

What is the current clinical-trials state for peginterferon alfa-2a?

Peginterferon alfa-2a has a mature development footprint focused on chronic hepatitis B (HBV) and chronic hepatitis C (HCV), with the bulk of late-stage activity occurring in earlier eras of interferon-based regimens. Current “new-start” volume for peginterferon alfa-2a is limited because treatment standards for HCV moved to direct-acting antivirals (DAAs), which displaced interferon-containing regimens. For HBV, interferon-based therapy still appears in comparative designs, but new trials are typically small, investigator-led, or focused on specific endpoints (immunologic markers, response durability, or combination strategies) rather than broad late-stage registrational programs.

Implication for monitoring: Companies and investors should treat peginterferon alfa-2a as a label- and guideline-maintained asset rather than an innovation pipeline driver. Clinical-trials value comes mainly from head-to-head persistence, retreatment data, and subgroup performance in viral kinetics and immunologic endpoints, not from new efficacy breakthroughs expected to expand the drug’s market structurally.

Where does peginterferon alfa-2a sit in the market today?

Peginterferon alfa-2a is a well-established branded interferon product globally. The market has two distinct demand drivers:

1. HCV (historical core, now structurally reduced)
   DAAs compressed interferon addressable demand. Countries that adopted DAAs widely saw rapid substitution, pushing peginterferon alfa-2a into residual-use segments (where DAAs are not accessible, where payer rules still permit interferon in limited lines, or where specific clinical scenarios keep interferon in use).

2. HBV (more persistent but narrower growth profile)
   Peginterferon alfa-2a retains use in defined HBV populations, particularly where finite-duration therapy and immune response endpoints align with clinician and guideline preferences. Growth is constrained by long-term nucleos(t)ide analog (NA) dominance (entecavir, tenofovir alafenamide, tenofovir disoproxil fumarate), which are typically first-line for many treatment algorithms.

Market positioning consequence: Peginterferon alfa-2a operates in a mature, price-pressured, and politically sensitive reimbursement environment. Volume depends on country-by-country uptake of DAAs (for HCV) and HBV treatment pathways (for HBV), not on new clinical differentiation.

What is the competitive landscape that shapes projection?

Peginterferon alfa-2a competes in two modalities:

HCV arena

• DAAs as the dominant standard.
• Peginterferon alfa-2a remains relevant in constrained geographies and specific access-limited settings, but it does not compete on efficacy against DAA regimens when DAAs are available.

HBV arena

• NAs as the chronic backbone therapy in many guidelines.
• Peginterferon alfa-2a competes on finite treatment concepts and immunologic response targets, which drives niche demand rather than broad expansion.

How do label and guideline dynamics affect demand?

Guideline evolution is the central demand regulator.

HCV displacement

As DAA uptake accelerated globally, peginterferon alfa-2a demand declined. The economic shift is durable: DAAs changed treatment from long interferon-based courses to short oral regimens with high cure rates and fewer safety barriers.

HBV persistence through immune-based endpoints

HBV guidelines often preserve interferon options for selected patients, but most patients are treated chronically with NAs. That keeps peginterferon alfa-2a in a smaller segment with steadier but limited growth.

Market sizing: what drives a realistic projection?

A credible projection for peginterferon alfa-2a must be built on three measurable levers:

1. Country adoption rates for DAAs (HCV substitution pace)
2. HBV guideline allocation to interferon versus NA strategies
3. Reimbursement access and price compression in mature markets

Because peginterferon alfa-2a is a legacy biologic with no clear “next-generation” product-cycle catalyst, the projection profile is typically:

• Flat-to-declining volume in markets where DAAs are widely adopted.
• Stable demand in limited access or specific HBV subpopulations.
• Margin pressure due to biosimilar/interchangeability and payer-led cost controls where applicable.

Projection scenarios (directional, decision-ready)

The table below frames three practical scenarios used by commercial teams to set planning ranges. It is directional and tied to known structural dynamics (DAA substitution and interferon niche retention).

Scenario	HCV environment	HBV environment	PEG-IFN alfa-2a net market trend (next 3-5 years)	Primary driver
Base case	High DAA access, limited residual interferon use	Interferon preserved for selected patients	Low single-digit decline or flat	Substitution offset by niche HBV
Bear case	Faster DAAs + tighter formularies for interferon	Further shift to NAs and finite-therapy alternatives	Mid single-digit to higher decline	Payer and guideline reallocation
Bull case	Slower DAA rollout in pockets; stable HBV interferon allocation	Greater uptake in immune-response programs	Mild growth or stable with better pricing	Access pockets and HBV subgroups

What does the compliance and safety profile imply for uptake?

Peginterferon alfa-2a’s safety burden (class effects: flu-like symptoms, neuropsychiatric events, cytopenias, thyroid dysfunction) constrains uptake and increases monitoring requirements. For an asset competing in an era of safer oral regimens (for HCV) and chronic NA therapy (for HBV), safety and logistics favor constrained utilization even when clinical efficacy is adequate for selected patients.

Commercial impact: demand is less elastic to modest efficacy improvements and more sensitive to:

• payer restrictions,
• clinician comfort,
• ability to monitor and manage adverse events,
• and availability of alternative regimens with lower monitoring burden.

Commercial takeaways for R&D and investment

Even without a high-volume current registrational pipeline, peginterferon alfa-2a can still hold strategic value under specific theses:

1. Lifecycle management (label and access)

   • Maintain or extend treatment positioning in HBV subgroups where finite-duration immune response is valued.
   • Target country segments where DAAs are delayed or interferon remains reimbursed.

2. Combination and sequencing

   • In HBV, any renewed positioning typically depends on immunologic or viral kinetics endpoints that justify combination or sequencing logic.
   • In HCV, the bar for interferon-based strategy is higher because DAAs dominate.

3. Operational efficiency

   • Lower cost-of-goods and dosing simplicity matters because competitors win on total treatment burden.

---

Key Takeaways

• Peginterferon alfa-2a is a mature, guideline-shaped therapy with limited “pipeline expansion” momentum.
• HCV demand is structurally compressed by DAAs; remaining use is mainly access- or policy-limited.
• HBV maintains a more durable niche, but it is smaller than NA-centric chronic therapy and therefore caps upside.
• Market projection is best modeled as flat-to-declining in most regions, with pockets of stability driven by HBV finite-therapy preference and uneven DAA rollout.

FAQs

1. Is peginterferon alfa-2a still a standard of care for HCV?
   No. DAAs dominate in most markets; interferon-based therapy persists only where access, reimbursement, or clinical constraints keep interferon in use.

2. What patient populations most support peginterferon alfa-2a demand in HBV?
   Subgroups where clinicians prioritize finite-duration therapy and immune response endpoints rather than lifelong NA suppression.

3. Why has peginterferon alfa-2a’s market shrunk over time?
   The shift from interferon to DAAs for HCV reduced both clinical need and payer incentives for interferon regimens.

4. What determines whether the drug shows stability versus continued decline?
   DAA access pace (HCV) and guideline allocation to interferon versus NA strategies (HBV), plus reimbursement rules.

5. Does the safety profile limit broader adoption?
   Yes. Interferon class adverse effects and monitoring requirements constrain use when safer alternatives exist.

---

References

[1] World Health Organization. Guidelines for the care and treatment of people with chronic hepatitis C infection. WHO, 2018.
[2] European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: Management of hepatitis B virus infection. J Hepatol, 2017 (updated recommendations through subsequent publications).
[3] AASLD/IDSA. Hepatitis C Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. (Guidance maintained and updated online).